Novartis And Daiichi Sankyo Obtain Japanese Price Listings, May Set Precedent For Combination Re-pricing
This article was originally published in PharmAsia News
Executive Summary
Japan's Central Social Medical Insurance Agency, also called Chuikyo, recently approved price listings for Novartis' and Daiichi Sankyo's respective potential blockbuster combination diabetes drugs, and the council also agreed to review drug pricing policy to encourage investment in drug innovation